PMID- 38422742
OWN - NLM
STAT- MEDLINE
DCOM- 20240313
LR  - 20240329
IS  - 1872-6968 (Electronic)
IS  - 0303-8467 (Linking)
VI  - 238
DP  - 2024 Mar
TI  - The investigation of killer-cell immunoglobulin-like receptors (KIRs) and their 
      HLA ligands in Iranian patients with myasthenia gravis.
PG  - 108171
LID - S0303-8467(24)00058-1 [pii]
LID - 10.1016/j.clineuro.2024.108171 [doi]
AB  - BACKGROUND: Myasthenia gravis (MG) is a disabling disease with the underlying 
      pathophysiology of auto-antibodies attacking the postsynaptic acetylcholine 
      receptors of neuromuscular junctions causing muscle weakness. Natural killer (NK) 
      cells are innate immune cells that play an important regulative role in immune 
      responses. The human killer-cell immunoglobulin-like receptors (KIRs) family is 
      one of the receptors on NK cells that can either activate or inhibit NK cells. 
      This study aimed to assess the possible role of KIR and their human leukocyte 
      antigen (HLA) ligand genes susceptibility to MG in Iranian patients. METHOD: One 
      hundred and sixty-three patients with MG diagnosis based on the presence of 
      clinical symptoms and laboratory tests and 400 healthy volunteers were studied. 
      We used the polymerase chain reaction (PCR) technique for genotyping 15 KIRs and 
      5 HLA genes. RESULTS: The results demonstrated that there was no significant 
      difference in the frequency of KIR genes and inhibitory KIR genotypes between 
      controls and patients. In MG patients, HLA-C1(Asn80) was significantly less 
      frequent than in matched controls. The frequency of HLA genotype number 7 was 
      significantly lower in MG cases, compared to the controls. Analysis of activating 
      KIR genotypes showed that genotype number 10 was significantly less frequent in 
      MG cases than in matched controls. CONCLUSION: Our results suggest that the 
      presence HLA-C1(Asn80) might play a protective role against the pathogenesis of 
      MG. The significantly decreased prevalence of one activating KIR genotype and one 
      of the HLA genotypes in MG cases suggest that these genotypes can reduce the risk 
      of MG development. To specifically reveal the impact of KIR and HLA in MG, more 
      studies are required.
CI  - Copyright (c) 2024. Published by Elsevier B.V.
FAU - Jalalvand, Mobina
AU  - Jalalvand M
AD  - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Beigmohammadi, Fereshteh
AU  - Beigmohammadi F
AD  - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Soltani, Samaneh
AU  - Soltani S
AD  - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Ehsan, Soroush
AU  - Ehsan S
AD  - Department of Neurology, Shariati Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Rajabkhah, Sahebeh
AU  - Rajabkhah S
AD  - Department of Neurology, Shariati Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Madreseh, Elham
AU  - Madreseh E
AD  - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran; Department of Epidemiology and Biostatistics, School of Public Health, 
      Tehran University of Medical Sciences, Tehran, Iran.
FAU - Akhtari, Maryam
AU  - Akhtari M
AD  - Tobacco Prevention and Control Research Center, National Research Institute of 
      Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Jamshidi, Ahmadreza
AU  - Jamshidi A
AD  - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Farhadi, Elham
AU  - Farhadi E
AD  - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran; Research Center for Chronic Inflammatory Diseases, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Mahmoudi, Mahdi
AU  - Mahmoudi M
AD  - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran; Research Center for Chronic Inflammatory Diseases, Tehran University of 
      Medical Sciences, Tehran, Iran. Electronic address: mahmoudim@tums.ac.ir.
FAU - Nafissi, Shahriar
AU  - Nafissi S
AD  - Department of Neurology, Shariati Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran; Neuromuscular Research Center, Tehran University of 
      Medical Sciences, Tehran, Iran. Electronic address: nafisi@sina.tums.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20240213
PL  - Netherlands
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
RN  - 0 (Immunoglobulins)
RN  - 0 (Ligands)
RN  - 0 (Receptors, KIR)
RN  - 0 (HLA Antigens)
RN  - Iranian people
SB  - IM
MH  - Humans
MH  - Genotype
MH  - Immunoglobulins/genetics
MH  - Iran
MH  - Ligands
MH  - *Myasthenia Gravis/genetics
MH  - *Receptors, KIR/genetics
MH  - HLA Antigens/genetics
MH  - Middle Eastern People/genetics
OTO - NOTNLM
OT  - Genetic association
OT  - Killer cell immunoglobulin-like receptor
OT  - Myasthenia gravis
OT  - Natural killer cell
COIS- Declaration of Competing Interest The authors declare that there is no conflict 
      of interest.
EDAT- 2024/03/01 01:22
MHDA- 2024/03/13 06:46
CRDT- 2024/02/29 18:08
PHST- 2023/10/01 00:00 [received]
PHST- 2024/01/31 00:00 [revised]
PHST- 2024/02/08 00:00 [accepted]
PHST- 2024/03/13 06:46 [medline]
PHST- 2024/03/01 01:22 [pubmed]
PHST- 2024/02/29 18:08 [entrez]
AID - S0303-8467(24)00058-1 [pii]
AID - 10.1016/j.clineuro.2024.108171 [doi]
PST - ppublish
SO  - Clin Neurol Neurosurg. 2024 Mar;238:108171. doi: 10.1016/j.clineuro.2024.108171. 
      Epub 2024 Feb 13.